secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0000950170-23-027129
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts exa-cel BLAs; pivotal trials meet primary endpoints in SCD and TDT
------------------------------------------------------------------------------

- FDA granted Priority Review for SCD (PDUFA Dec 8, 2023) and Standard Review for TDT (PDUFA Mar 30, 2024).
- In TDT, 24/27 (88.9%) achieved transfusion-independence ≥12 months; mean duration 20.5 months.
- In SCD, 16/17 (94.1%) achieved freedom from vaso-occlusive crises ≥12 months; mean duration 18.7 months.
- Safety profile consistent with busulfan conditioning; no deaths or discontinuations related to exa-cel.
- Data from 83 patients (48 TDT, 35 SCD) with follow-up up to 43.7 months presented at EHA 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023027129/0000950170-23-027129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023027129/crsp-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer